Jafron Biomedical Co Ltd - Asset Resilience Ratio

Latest as of March 2026: 39.15%

Jafron Biomedical Co Ltd (300529) has an Asset Resilience Ratio of 39.15% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Jafron Biomedical Co Ltd (300529) strategic asset index to assess the company's strategic physical and investment asset allocation.

Liquid Assets

CN¥2.16 Billion
≈ $316.31 Million USD Cash + Short-term Investments

Total Assets

CN¥5.52 Billion
≈ $807.93 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2016–2025)

This chart shows how Jafron Biomedical Co Ltd's Asset Resilience Ratio has changed over time. See 300529 net asset quality score to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Jafron Biomedical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 300529 stock market capitalisation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥2.16 Billion 39.15%
Total Liquid Assets CN¥2.16 Billion 39.15%

Asset Resilience Insights

  • Very High Liquidity: Jafron Biomedical Co Ltd maintains exceptional liquid asset reserves at 39.15% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

Jafron Biomedical Co Ltd Industry Peers by Asset Resilience Ratio

Compare Jafron Biomedical Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Medacta Group SA
SW:MOVE
Medical Devices 0.86%
Double Medical Technology Inc
SHE:002901
Medical Devices 12.59%
Shenzhen New Industries Biomedical
SHE:300832
Medical Devices 9.95%
Sinocare Inc
SHE:300298
Medical Devices 3.53%
Xiangyu Medical Co. Ltd. A
SHG:688626
Medical Devices 1.53%
INKON Life Technology Co Ltd
SHE:300143
Medical Devices 5.73%
HOB Biotech Group Corp Ltd
SHG:688656
Medical Devices 2.62%
Polynovo Ltd
AU:PNV
Medical Devices 0.04%

Annual Asset Resilience Ratio for Jafron Biomedical Co Ltd (2016–2025)

The table below shows the annual Asset Resilience Ratio data for Jafron Biomedical Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 0.00% CN¥61.82K
≈ $9.05K
CN¥5.41 Billion
≈ $791.50 Million
-11.02pp
2024-12-31 11.02% CN¥593.07 Million
≈ $86.79 Million
CN¥5.38 Billion
≈ $787.77 Million
+7.90pp
2021-12-31 3.12% CN¥150.01 Million
≈ $21.95 Million
CN¥4.81 Billion
≈ $703.87 Million
-4.57pp
2016-12-31 7.69% CN¥100.00 Million
≈ $14.63 Million
CN¥1.30 Billion
≈ $190.21 Million
--
pp = percentage points

About Jafron Biomedical Co Ltd

SHE:300529 China Medical Devices
Market Cap
$1.83 Billion
CN¥12.54 Billion CNY
Market Cap Rank
#6604 Global
#1444 in China
Share Price
CN¥15.70
Change (1 day)
-0.63%
52-Week Range
CN¥15.70 - CN¥24.54
All Time High
CN¥96.12
About

Jafron Biomedical Co.,Ltd. engages in the research, development, production, and sale of blood purification products for hemadsorption field worldwide. The company offers therapies for kidney, liver, and critical diseases, as well as poisoning. It also provides HA series disposable hemoperfusion cartridge; BS series disposable plasma bilirubin perfusion adsorption column; blood purification machi… Read more